biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Forcing Bioasis to Answer

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Jan 16, 2023 8:49pm

77 Views

Post# 35226918

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Forcing Bioasis to Answer

BTI and Midatech holders received 33% of the upside of Biodexa, as outlined, and that appears reasonable under the very difficult circumstances.

There has been significant improvement in stocks since the deal was put together. Midatech's CEO said he could have put together an alternative financial package. Perhaps the second warrant could be eliminated; but the financing needs to be priced to clear US$20 million at least which can be further topped up by deals on xB3 and Q-Sphera during the year. We want a decisively strong balance sheet to break the financial misery that has plagued this company the last ten years. A strong balance sheet can support confidence in the stock. BTI traded at a perpetual discount because it was in a perpetual financial emergency.

emmitfitzhume wrote: So you contend that 1.62% of future XB3 success compared to where we were 5 weeks ago is an acceptable term for current shareholders?

I think that a more equitable deal could have been explored.

Or, XB3 simply doesn’t work. That is the only scenario in which such a deal makes sense.

Seems rather clear to me.